Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Phase 3 Completed 682 enrolled AGO Research GmbH ARCAGY/ GINECO GROUP · collab Arbeitsgemeinschaft Gynaekologische Onkologie Austria · collab Australia New Zealand Gynaecological Oncology Group · collab Scottish Gynaecological Cancer Study Group · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.

Timeline

Start: 2013-05
Primary completion: 2021-01
Completion: 2021-01

Outcome

Met primary endpoint

paper Median progression-free survival was 13·3 months (95% CI 11·7-14·2) in the experimental group versus 11·6 months (11·0-12·7) in the standard group (hazard ratio 0·81, 95% CI 0·68-0·96; p=0·012). PMID 32305099 ↗

Publications

Results Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marme F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Carboplatin	Small molecule	4 unknown	Intravenous
Subject	Pegylated liposomal doxorubicin	Unknown	30 mg/m2	—

Indications

No indication recorded.